Tuesday broker round-up UPDATE
29th Jan 2013 07:26
Anglo American: JP Morgan takes price target from 1630p to 1680p, while its underweight rating remains unchanged. ARM Holdings: Jefferies raises target price from 693p to 805p keeping a hold recommendation. Astra Zaneca: Barclays ups target price from 3100p to 3200p and retains an equal-weight rat
Read moreSunday share tips: Tullow Oil, AstraZeneca, Aviva
27th Jan 2013 17:20
It may be time for Aidan Heavey to step aside at Tullow Oil. The former accountant, 59, is rightly feted as one of the oil industry's great entrepreneurs. Beginning with a tiny start-up in 1986 the Irishman turned Tullow into one of the most successful explorers in the world. Its 10.7bn pound market
Read moreSunday newspaper round-up: Barclays, Carney, BP
27th Jan 2013 16:23
Barclays is planning a swoop on the financial markets to raise billions of pounds of new capital ahead of a showdown with the Bank of England. Sources close to the bank say it could launch the move within weeks to kill off questions about its financial strength. All Britain's banks are on edge as th
Read moreTuesday newspaper round-up: AstraZeneca, Japan, Carpetright...
22nd Jan 2013 06:56
Health insurers and doctors in the United States are turning up their noses at AstraZeneca's much-vaunted new heart drug, according to a leading broker. Analysts at Société Générale forecast yesterday that sales of Brilinta would reach only 304 million dollars by 2015 ? barely a third of the market'
Read moreMonday broker round-up UPDATE
21st Jan 2013 07:02
Abbey Protection: Numis increases target price from 90p to 120p and upgrades to add. Admiral: Goldman Sachs upgrades to buy from neutral, raising its price target to 1500p from 1160p before. Aggreko: Bank of America lowers target price from 2700p to 1950p and downgrades to neutral. Anglo Americ
Read moreSunday newspaper round-up: RBS, HMV, Japan
20th Jan 2013 16:31
Top managers at the RBS investment bank, including its Chief Executive, John Hourican, who it has since emerged was planning to leave after reshaping the business - may quit to take responsibility for the disregard shown for the market even though they are not personally culpable. While the evidence
Read moreWednesday newspaper round-up: AstraZeneca, Facebook, PPI claims...
16th Jan 2013 06:54
The new boss of AstraZeneca has dismissed two of the drugs company's leadership team as part of a shake-up intended to tackle flagging sales and scientific setbacks. The head of research and development, Martin Mackay, and its global commercial chief, Tony Zook, are to leave the pharmaceuticals grou
Read moreMonday newspaper round-up: AstraZeneca, North Sea jobs, Glaxo...
14th Jan 2013 06:56
The Science Minister has lobbied the NHS to increase its use of an AstraZeneca heart medicine, amid mounting political concern about the drugs company's commitment to British jobs. David Willetts has urged health officials to accelerate the uptake of Brilique, a blood thinner used to treat patients
Read moreCourt upholds legal ruling on AstraZeneca 'Crestor' patent
17th Dec 2012 11:13
On Friday December 14th, the Court of Appeals for the Federal Circuit announced that it had upheld the District Court in Delaware's finding that biopharmaceutical business AstraZeneca's substance patent protecting Crestor is valid and enforceable. The ruling follows legal wranglings dating back fi
Read moreLondon close: 'Fiscal cliff' concerns keep markets under pressure
13th Dec 2012 16:45
- Boehner says White House not serious about 'cliff' - Stocks shrug off Fed stimulus - Centamin plummets after mine suspension Stocks markets across Europe took a breather on Thursday, following a strong performance over the last month, as investors digested stimulus plans by the Federal Reserve an
Read moreFTSE 100 movers: Wood Group falls as update comes in mixed
13th Dec 2012 15:48
Energy services giant Wood Group fell after it reported mixed trading in its Upstream division and despite saying it expects to deliver good growth this year, with overall conditions in energy markets remaining 'favourable'. AstraZeneca fell after revealing that its experimental drug for rheumatoi
Read moreWednesday broker round-up UPDATE
12th Dec 2012 07:25
AMEC: Credit Suisse reduces target price from 1300p to 1250p reiterating an outperform rating. Anglo American: Barclays upgrades to equal-weight with a target price of 1970p. Ashtead Group: Barclays raises target price from 352p to 434p and reiterates an overweight rating. ASOS: HSBC raises targe
Read moreEU Court upholds 52.5m euro fine against AstraZeneca Group
6th Dec 2012 11:18
Global biopharmaceutical group AstraZeneca (AZ) has lost an appeal over a 52.5m euro fine relating to the way that its subsidiaries AstraZeneca AB and AstraZeneca Plc marketed an ulcer-treating drug. The case, which dates back to 2005 and has been subject to two appeals, surrounds the way that the
Read moreMonday broker round-up UPDATE
3rd Dec 2012 07:16
ARM Holdings: Exane BNP Paribas upgrades from neutral to buy. Ashtead Group: Bank of America starts with a target price of 460p and a buy recommendation. AstraZaneca: Berenberg raises target price from 3080p to 3100p; hold recommendation kept. Balfour Beatty: Investec reduces target price from 21
Read moreDiageo CEO reduces stake further
22nd Nov 2012 16:17
The Chief Executive Officer of Diageo, the FTSE 100 drinks giant, has sold another slice of his stake in the company, reducing his holding to 729,582 shares. Paul Walsh, who was appointed to the role of CEO in 2000, traded in 20,000 shares for 1,850.00p each, worth a total of £370,000. The trans
Read more